Global Legal Chronicle: Urovant Sciences’ US$681 Million Merger With Sumitovant Biopharma

十二月 02, 2020

O’Melveny advised Urovant Sciences on its US$681 million definitive merger agreement with Sumitovant Biopharma. Urovant is a biopharmaceutical company focused on developing and commercializing therapies for urologic conditions, this article reported.

The cross-practice O’Melveny team was led by partner Mark Peterson, counsel Noah Kornblith and Cem Surmeli, and associate Mollie Yeh. Partners Andrew Dolak, Chris Del Rosso, Bob Fisher, Shelly Heyduk, and Jennifer Taylor, counsel Aaron Cha, and associate John Chong also advised on the deal.

Read the full article here.